RATIONALE: North American occupational health programs that switched from the tuberculin skin test (TST) to IFN-γ release assays for latent tuberculosis screening are reporting challenges with interpretation of serial testing results in healthcare workers (HCWs). However, limited data exist on the reproducibility of serial IFN-γ release assay results in low-risk HCWs. OBJECTIVES: To evaluate the short-term reproducibility of QuantiFERON-TB Gold In-Tube (QFT) in a large cohort of HCWs and to define a QFT cutoff yielding a conversion rate equivalent to historical TST rates. METHODS: We retrospectively evaluated the QFT results from HCWs with two or more QFT tests performed between June 2008 and July 2010 at an academic institution. Outcome measures were proportions of reproducibility, quantitative results, and conversion rates with alternate QFT cutoffs. MEASUREMENTS AND MAIN RESULTS: A total of 9,153 HCWs with two or more QFT tests were included in the analysis. Of 8,227 individuals with a negative result, 4.4% (n = 361) converted their QFT result over 2 years. A total of 261 (72.3%) of the HCWs with conversions underwent repeat short-term testing after the first positive result with 64.8% reverting (n = 169). An IFN-γ cutoff of 5.3 IU/ml or higher (manufacturer's cutoff is ≥0.35 IU/ml) yielded a conversion rate of 0.4%, equal to our institution's historical TST conversion rate. CONCLUSIONS: The manufacturer's definition of QFT conversion results in an inflated conversion rate that is incompatible with our low-risk setting. A significantly higher QFT cutoff value is needed to match the historical TST conversion rate. Nonreproducible conversions in most converters suggested false-positive results.
RATIONALE: North American occupational health programs that switched from the tuberculin skin test (TST) to IFN-γ release assays for latent tuberculosis screening are reporting challenges with interpretation of serial testing results in healthcare workers (HCWs). However, limited data exist on the reproducibility of serial IFN-γ release assay results in low-risk HCWs. OBJECTIVES: To evaluate the short-term reproducibility of QuantiFERON-TB Gold In-Tube (QFT) in a large cohort of HCWs and to define a QFT cutoff yielding a conversion rate equivalent to historical TST rates. METHODS: We retrospectively evaluated the QFT results from HCWs with two or more QFT tests performed between June 2008 and July 2010 at an academic institution. Outcome measures were proportions of reproducibility, quantitative results, and conversion rates with alternate QFT cutoffs. MEASUREMENTS AND MAIN RESULTS: A total of 9,153 HCWs with two or more QFT tests were included in the analysis. Of 8,227 individuals with a negative result, 4.4% (n = 361) converted their QFT result over 2 years. A total of 261 (72.3%) of the HCWs with conversions underwent repeat short-term testing after the first positive result with 64.8% reverting (n = 169). An IFN-γ cutoff of 5.3 IU/ml or higher (manufacturer's cutoff is ≥0.35 IU/ml) yielded a conversion rate of 0.4%, equal to our institution's historical TST conversion rate. CONCLUSIONS: The manufacturer's definition of QFT conversion results in an inflated conversion rate that is incompatible with our low-risk setting. A significantly higher QFT cutoff value is needed to match the historical TST conversion rate. Nonreproducible conversions in most converters suggested false-positive results.
Authors: Felix C Ringshausen; Albert Nienhaus; José Torres Costa; Heiko Knoop; Stephan Schlösser; Gerhard Schultze-Werninghaus; Gernot Rohde Journal: Clin Vaccine Immunol Date: 2011-05-18
Authors: John Z Metcalfe; Adithya Cattamanchi; Charles E McCulloch; Justin D Lew; Ngan P Ha; Edward A Graviss Journal: Am J Respir Crit Care Med Date: 2012-10-26 Impact factor: 21.405
Authors: José Torres Costa; Rui Silva; Raul Sá; Maria João Cardoso; Albert Nienhaus Journal: Int Arch Occup Environ Health Date: 2010-08-19 Impact factor: 3.015
Authors: Alice Zwerling; Andrea Benedetti; Mihaela Cojocariu; Fiona McIntosh; Filomena Pietrangelo; Marcel A Behr; Kevin Schwartzman; Dick Menzies; Madhukar Pai Journal: PLoS One Date: 2013-01-31 Impact factor: 3.240
Authors: Jason R Andrews; Elisa Nemes; Michele Tameris; Bernard S Landry; Hassan Mahomed; J Bruce McClain; Helen A Fletcher; Willem A Hanekom; Robin Wood; Helen McShane; Thomas J Scriba; Mark Hatherill Journal: Lancet Respir Med Date: 2017-02-16 Impact factor: 30.700
Authors: Jason R Andrews; Mark Hatherill; Hassan Mahomed; Willem A Hanekom; Monica Campo; Thomas R Hawn; Robin Wood; Thomas J Scriba Journal: Am J Respir Crit Care Med Date: 2015-03-01 Impact factor: 21.405
Authors: Saloua Tagmouti; Madeline Slater; Andrea Benedetti; Sandra V Kik; Niaz Banaei; Adithya Cattamanchi; John Metcalfe; David Dowdy; Richard van Zyl Smit; Nandini Dendukuri; Madhukar Pai; Claudia Denkinger Journal: Ann Am Thorac Soc Date: 2014-10
Authors: Madhukar Pai; Claudia M Denkinger; Sandra V Kik; Molebogeng X Rangaka; Alice Zwerling; Olivia Oxlade; John Z Metcalfe; Adithya Cattamanchi; David W Dowdy; Keertan Dheda; Niaz Banaei Journal: Clin Microbiol Rev Date: 2014-01 Impact factor: 26.132
Authors: Madeline Slater; Minh-Chi Tran; Lauren Platt; Lien T Luu; Ha T Phan; Phuong T Pham; Tam B Do; Hanh T Nguyen; Rajiv L Gaur; Julie Parsonnet; Adithya Cattamanchi; Robert Luo; Payam Nahid; Niaz Banaei Journal: Diagn Microbiol Infect Dis Date: 2015-05-19 Impact factor: 2.803
Authors: Leonardo Martinez; Nathan C Lo; Olivia Cords; Philip C Hill; Palwasha Khan; Mark Hatherill; Anna Mandalakas; Alexander Kay; Julio Croda; C Robert Horsburgh; Heather J Zar; Jason R Andrews Journal: Lancet Respir Med Date: 2019-05-08 Impact factor: 30.700